CoChat

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

Open access

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index; 23 of the 52 sources its claims cite were checked for support.

Abstract

Objective: To evaluate the cardiovascular and renal benefits of finerenone, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) with network meta-analysis. Methods: Systematic literature searches were conducted of PubMed, Cochrane Library, Web of Science, Medline and Embase covering January 1, 2000 to December 30, 2021. Randomized control trials (RCTs) comparing finerenone, SGLT-2i and GLP-1 RA in diabetics with CKD were selected. We performed a network meta-analysis to compare the two drugs and finerenone indirectly. Results were reported as risk ratio (RR) with corresponding 95% confidence interval (CI). Results: 18 RCTs involving 51,496 patients were included. Finerenone reduced the risk of major adverse cardiovascular events (MACE), renal outcome and hospitalization for heart failure (HHF) (RR [95% CI]; 0.88 [0.80–0.97], 0.86 [0.79–0.93], 0.79 [0.67,0.92], respectively). SGLT-2i were associated with reduced risks of MACE (RR [95% CI]; 0.84 [0.78–0.90]), renal outcome (RR [95% CI]; 0.67 [0.60–0.74], HHF (RR [95% CI]; 0.60 [0.53–0.68]), all-cause death (ACD) (RR [95% CI]; 0.89 [0.81–0.91]) and cardiovascular death (CVD) (RR [95% CI]; 0.86 [0.77–0.96]) compared to placebo. GLP-1 RA were associated with a lower risk of MACE (RR [95% CI]; 0.86 [0.78–0.94]). SGLT2i had significant effect in comparison to finerenone (finerenone vs SGLT2i: RR [95% CI]; 1.29 [1.13–1.47], 1.31 [1.07–1.61], respectively) and GLP-1 RA (GLP-1 RA vs SGLT2i: RR [95% CI]; 1.36 [1.16–1.59], 1.49 [1.18–1.89], respectively) in renal outcome and HHF. Conclusions: In patients with T2DM and CKD, SGLT2i, GLP-1 RA and finerenone were comparable in MACE, ACD and CVD. SGLT2i significantly decreased the risk of renal events and HHF compared with finerenone and GLP-1 RA. Among GLP-1 RA, GLP-1 analogues showed significant effect in reducing cardiovascular events compared with exendin-4 analogues.

Overview

CoChat Summary

TL;DR

In adults with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), this network meta-analysis of 18 RCTs and 51,496 patients found that SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone all reduced MACE versus placebo, while SGLT2 inhibitors also reduced renal outcome, hospitalization for heart failure (HHF), all-cause death (ACD), and cardiovascular death (CVD). SGLT2 inhibitors significantly outperformed finerenone and GLP-1 receptor agonists for renal outcome and HHF.

Key findings

  • Finerenone reduced MACE (RR 0.88, 95% CI 0.80–0.97), renal outcome (RR 0.86, 95% CI 0.79–0.93), and HHF (RR 0.79, 95% CI 0.67–0.92) versus placebo, with a tendency to reduce ACD (RR 0.90, 95% CI 0.80–1.00).
  • SGLT2 inhibitors reduced MACE (RR 0.84, 95% CI 0.78–0.90), renal outcome (RR 0.67, 95% CI 0.60–0.74), HHF (RR 0.60, 95% CI 0.53–0.68), ACD (RR 0.89, 95% CI 0.81–0.99), and CVD (RR 0.86, 95% CI 0.77–0.96) versus placebo. GLP-1 receptor agonists reduced MACE (RR 0.86, 95% CI 0.78–0.94) but not renal outcome, HHF, ACD, or CVD versus placebo.
  • SGLT2 inhibitors were significantly better than finerenone and GLP-1 receptor agonists for renal outcome and HHF: finerenone vs SGLT2i RR 1.29 (95% CI 1.13–1.47) for renal outcome and 1.31 (95% CI 1.07–1.61) for HHF; GLP-1 RA vs SGLT2i RR 1.36 (95% CI 1.16–1.59) for renal outcome and 1.49 (95% CI 1.18–1.89) for HHF. MACE, ACD, and CVD were comparable among the three drug classes.
  • Among individual interventions, liraglutide ranked among the most effective for MACE (RR 0.69, 95% CI 0.58–0.82), ACD (RR 0.76, 95% CI 0.62–0.93), and CVD (RR 0.69, 95% CI 0.52–0.90); dapagliflozin, empagliflozin, and canagliflozin were among the most effective for renal outcome; ertugliflozin was among the most effective for HHF.

Methods

  • Systematic searches of PubMed, Cochrane Library, Web of Science, Medline, and Embase from January 1, 2000 to December 30, 2021 identified randomized controlled trials comparing finerenone, SGLT2 inhibitors, or GLP-1 receptor agonists with placebo in adults with T2DM and/or CKD; 18 RCTs involving 51,496 patients were included.
  • Network meta-analysis was performed in Stata version 15.0, reporting risk ratios with 95% confidence intervals; outcomes were MACE, renal outcome, HHF, ACD, and CVD. Risk of bias was assessed with RoB 2.0, and evidence certainty with GRADE and a minimally contextualized framework.
  • No outcome had a closed loop, so comparisons among finerenone, SGLT2 inhibitors, and GLP-1 receptor agonists relied on indirect evidence; a sensitivity analysis excluded the Cherney 2021 trial because it enrolled patients with severe CKD (eGFR 15–30 ml/min/1.73 m²).

Limitations

  • The authors state that the analysis was based on indirect comparisons and requires validation by head-to-head trials comparing finerenone with SGLT2 inhibitors and GLP-1 receptor agonists.
  • The authors note that some included studies were subgroup analyses of RCTs, raising concern that patients with T2DM and CKD may not have been completely randomized; there were also more patients in SGLT2 inhibitor studies than in GLP-1 receptor agonist or finerenone studies, and baseline eGFR in Cherney 2021 differed from other studies.
  • The authors did not assess albuminuria, so effects on albuminuria in patients with diabetes and CKD could not be investigated; the text also makes evident that GRADE downgraded SGLT2i vs finerenone and SGLT2i vs GLP-1 RA comparisons for intransitivity because only indirect evidence was available.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12933-022-01676-5

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Fig.1 PRISMA flowchart
Fig.1 PRISMA flowchartCC BY · PubMed Central
Fig.2 Detailed risk of bias in each study
Fig.2 Detailed risk of bias in each studyCC BY · PubMed Central
Fig.3 Network plot
Fig.3 Network plotCC BY · PubMed Central
Fig.4 Network meta-analysis reporting RR for MACE in patients with T2DM and CKD
Fig.4 Network meta-analysis reporting RR for MACE in patients with T2DM and CKDCC BY · PubMed Central
Fig.5 Network meta-analysis reporting RR for renal outcome in patients with T2DM and CKD
Fig.5 Network meta-analysis reporting RR for renal outcome in patients with T2DM and CKDCC BY · PubMed Central
Fig.6 Network meta-analysis reporting RR for HHF in patients with T2DM and CKD
Fig.6 Network meta-analysis reporting RR for HHF in patients with T2DM and CKDCC BY · PubMed Central
Fig.7 Network meta-analysis reporting RR for ACD in patients with T2DM and CKD
Fig.7 Network meta-analysis reporting RR for ACD in patients with T2DM and CKDCC BY · PubMed Central
Fig.8 Network meta-analysis reporting RR for CVD in patients with T2DM and CKD
Fig.8 Network meta-analysis reporting RR for CVD in patients with T2DM and CKDCC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 0 Not valid · 14 Not checked · 159 Own results and interpretations

141 more claims

Create a free account to see all 181 claims and to verify the 29 references still open.

See all claims — free account
  • Probably not a substantial claim. 25
  • It may state two separate claims as one. 12
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 7 · the rest aren’t loaded

2 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 84 references

Research works printed but not linked: 1

  1. International Diabetes Federation. IDF diabetes atlas. 10th ed. Brussels: International Diabetes Federation; 2021.

Cited by

See all 107

Metadata

Authors
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., & Zhao, J.
Affiliations
  • Beijing University of Chinese Medicine (CN)
  • Xiyuan Hospital (CN)
  • University of Lucerne (CH)
  • Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN)
Corresponding author
  • Wang, Shidong
  • Zhao, Jinxi
Venue
Cardiovascular Diabetology
Published
2022-11-05
Volume
21
Issue
1
Pages
232-232
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4308246065
Cited by
96
References
83
Citations by year
2026: 23 · 2025: 29 · 2024: 31 · 2023: 13
FWCI
13.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the National Natural Science Foundation of China (82074354)
  • the Natural Science Foundation of Beijing Municipality (7222278)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, chronic kidney disease, major adverse cardiovascular events, heart failure hospitalization, all-cause mortality, cardiovascular mortality, renal outcomes, drug comparison, renin-angiotensin system blockade, mineralocorticoid receptor antagonists, renal protection, cardioprotection
MeSH terms
Glucagon-Like Peptide-1 Receptor, Network Meta-Analysis, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Naphthyridines, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. https://app.cochat.ai/papers/10.1186/s12933-022-01676-5
The paper
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., & Zhao, J. (2022). Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-022-01676-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.